Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. have received FDA approval to market a 'digital pill' technology to treat mental health disorders. Abilify Mycite is a drug-device combination product that consists of Tokyo-based Otsuka's oral aripiprazole tablets, embedded with Redwood City, Calif.-based Proteus' ingestible event marker sensor. Otsuka's Abilify is used to treat depression, bipolar disorder and schizophrenia.

Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. have received FDA approval to market what they call 'digital pill' technology to treat mental health disorders. Abilify Mycite is a drug-device combination product that consists of Tokyo-based Otsuka's oral aripiprazole tablets, embedded with Redwood City, Calif.-based Proteus' ingestible event marker sensor.

Neovasc Inc. is offering up about $65 million worth of common shares and warrants that could help it handle litigation related to its Tiara mitral valve technology and clinical trials. The Vancouver-based company priced the underwritten offering of 6,609,588 series A units and 19,066,780 series B units, at a price of $1.46 per unit.

Tear Film Innovations Inc. (TFI) has completed its $9 million series A preferred stock funding round led by Visionary Ventures Fund L.P. and Tigris Ventures LLC. The San Diego-based company will use the funding to help with the commercialization of its Ilux system, once it receives FDA clearance.

Second Sight Medical Products Inc.'s Orion Cortical Visual Prosthesis system could reach a much larger patient population suffering from severe to profound retinitis pigmentosa once the implant clears regulatory hurdles. The Sylmar, Calif.-based firm has received full approval from the FDA to begin a five-patient feasibility clinical study for the device, which could restore sight to blind patients.